только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 3 / 6
Страница 1 / 1

Список литературы

  1. Kjaer SK., Frederiksen K., Munk C., Iftner T. Long-term abcolut risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.// J Natl Cancer Inst. – 2010. – V.102, N 19. – P. 1478–88.
  2. Rodríguez AC., Schiffman M., Herrero R. et all. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. // J Natl Cancer Inst. – 2010. – V. 102, N 5. – P. 315– 24.
  3. Parkin DMю, Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. // CA Cancer J Clin. – 2005. – V. 55, N 2. – P. 74–108.
  4. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. // Int J Cancer. – 2007. – V. 120, N 4. – P. 885–91.
  5. Dugué PA., Rebolj M., Garred P., Lynge E. Immunosuppression and risk of cervical cancer. // Expert Rev Anticancer Ther. – 2013. – V. 13, N 1. – P. 29–42.
  6. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 г. (заболеваемость и смертность) // М.: МНИОИ им. П.А.Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, - 2018. - 250 с.
  7. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. (Internet)
  8. Kurman RJ., Carcangiu ML., Harrington CS., Young RH, eds. WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press; 2014. World Health Organization Classification of Tumors. 4th edition.
  9. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.// Int J Gynecol Obstet. – 2009. – V. 105, N 2. – P. 103–4.
  10. Wiebea E., Dennyb L., Thomasa G. FIGO cancer report 2012. Cancer of the cervix uteri. // Int J Gynecol Obstet. – 2012. – V. 119, S 2. – P. S100–S109.
  11. Hricak H., Gatsonis C., Chi DS. et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651 – Gynecologic Oncology Group 183. // J Clin Oncol. – 2005. – V. 23, N 36. – P. 9329–37.
  12. Bipat S., Glas AS, van der Velden J. et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. // Gynecol Oncol. – 2003. – V. 91, N 1. – P. 59–66.
  13. Amit A., Schink J., Reiss A. et al. PET/CT in gynecologic cancer: present applications and future prospects--a clinician's perspective. // Obstet Gynecol Clin North Am. – 2011. – V. 38, N 1. – P. 1-21.
  14. Webb JC., Key CR., Qualls CR. et al. Population-based study of microinvasive adenocarcinoma of the uterine cervix. // Obstet Gynecol. – 2001. – V. 97, N 5, Pt 1. – P. 701–6.
  15. Elliott P., Coppleson M., Russell P. et al. Early invasive (FIGO stage IA) carcinoma of the cervix: a clinico-pathologic study of 476 cases. // Int J Gynecol Cancer. – 2000. – V. 10, N 1. – P. 42–52.
  16. Bouchard-Fortier G., Reade CJ., Covens A. Non-radical surgery for small early-stage cervical cancer. Is it time? // Gynecol Oncol. – 2014. – V. 132, N 3. – P. 624–7.
  17. Shepherd JH, Spencer C, Herod J, Ind TE. Radical vaginal trachelectomy as a fertility- sparing procedure in women with early-stage cervical cancercumulative pregnancy rate in a series of 123 women. // BJOG. – 2006. – V. 113, N 6. – P. 719–24.
  18. Landoni F., Maneo A., Colombo A., et al. Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. // Lancet. – 1997. – V. 350, N 9077. – P. 535–40.
  19. Sakuragi N., Satoh C., Takeda N. et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. // Cancer. – 1999, – V. 85, N 7. – P. 1547–54.
  20. Huang H., Liu J., Li Y. et al. Metastasis to deep obturator and para-aortic lymph nodes in 649 patients with cervical carcinoma. // Eur J Surg Oncol. – 2011. – V. 37, N 11. – P. 978–83.
  21. van Bommel PF., van Lindert AC., Kock HC. et al. A review of prognostic factors in early-stage carcinoma of the cervix (FIGO IB and IIA) and implications for treatment strategy. // Eur J Obstet Gynecol Reprod Biol. – 1987. – V. 26, N 1. – P. 69–84.
  22. Peters WA., Liu PY., Barrett RJ. et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. // J Clin Oncol. – 2000. – V. 18, N 8. – P. 1606–13.
  23. Rotman M., Sedlis A., Piedmonte MR. et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. // Int J Radiat Oncol Biol Phys. – 2006. – V. 65, N 1. – P, 169–76.
  24. Sedlis A., Bundy BN., Rotman MZ. et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. // Gynecol Oncol. – 1999. – V. 73, N 2. – P. 177–83.
  25. Lintner B., Saso S., Tarnai L. et al. Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter. // Int J Gynecol Cancer. – 2013. – V. 23, N 6. – P. 1065–70.
  26. Wethington SL., Sonoda Y., Park KJ. et al. Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. // Int J Gynecol Cancer. – 2013. – V. 23, N 6. – P. 1092–8.
  27. Varia MA., Bundy BN., Deppe G. et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. // Int J Radiat Oncol Biol Phys. – 1998. – V. 42, N 5. – P. 1015–23.
  28. Grigsby PW., Lu JD., Mutch DG. et al. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10. // Int J Radiat Oncol Biol Phys. – 1998. – V. 41, N 4. – P. 817–22.
  29. Landoni F., Maneo A., Cormio G. et al. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. // Gynecol Oncol. – 2001. – V. 80, N 1. – P. 3–12.
  30. Keys HM., Bundy BN., Stehman FB. et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. // N Engl J Med. – 1999. – V. 340, N 15. – P. 1154–61.
  31. Morris M., Eifel PJ., Lu J. et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. // N Engl J Med. – 1999. – V. 340, N 15. – P. 1137–43.
  32. Peters WA 3rd., Liu PY., Barrett RJ 2nd. et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. // J Clin Oncol. – 2000. – V. 18, N 8. – P. 1606–13.
  33. Whitney CW., Sause W., Bundy BN. et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. // J Clin Oncol. – 1999. – V. 17, N 5. – P. 1339–48.
  34. Rose PG., Bundy BN., Watkins EB. et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. // N Engl J Med. – 1999. – V. 340, N 15. – P. 1144–53.
  35. Rydzewska L., Tierney J., Vale CL. et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD007406.
  36. Ye Q., Yuan HX., Chen HL. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis. // J Cancer Res Clin Oncol. – 2013. – V. 139, N 11. – P. 1887–98.
  37. Hacker NF., Wain GV., Nicklin JL. Resection of bulky positive lymph nodes in patients with cervical carcinoma. // Int J Gynecol Cancer. – 1995. – V. 5, N 4. – P. 250–6.
  38. Kupets R., Thomas GM., Covens A. Is there a role for pelvic lymph node debulking in advanced cervical cancer? // Gynecol Oncol. – 2002. – V. 87, N 2. – P. 163–70.
  39. Perez CA., Grigsby PW., Castro-Vita H. et al. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. // Int J Radiat Oncol Biol Phys. – 1995. – V. 32, N 5. – P. 1275–88.
  40. Lanciano RM., Pajak TF., Martz K., Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. // Int J Radiat Oncol Biol Phys. – 1993. – V. 25, N 3. – P. 391–7.
  41. Dueñas-González A., Zarbá JJ., Patel F et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. // J Clin Oncol. – 2011. – V. 29, N 13. – P. 1678–85.
  42. Marnitz S., Dowdy S., Lanowska M. et al. Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers. // Int J Gynecol Cancer. – 2009. – V. 19, N 5. – P. 974–7.
  43. Berek JS., Howe C., Lagasse LD. et al. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. // Gynecol Oncol. – 2005. – V. 99, N 1. – P. 153–9.
  44. Goldberg GL., Sukumvanich P., Einstein MH. et al. Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). // Gynecol Oncol. – 2006. – V. 101, N 2. – P. 261–8.
  45. Morley GW., Hopkins MP., Lindenauer SM. et al. Pelvic exenteration, University of Michigan: 100 patients at 5 years. // Obstet Gynecol. – 1989. – V. 74, N 6. – P. 934–43.
  46. Hatano K., Sakai M., Araki H. et al. Image-Guided radiation dosimetry for cervical cancer versus classical point A dosimetry // Radiotherapy and Oncology. – 2008. – V. 88, N 2, – P. 241.
  47. Pötter R., Haie-Meder C., van Limbergen E. et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. // Radiotherapy and Oncology. – 2006. – V. 78. –P.67–77.
  48. ICRU report № 89 Prescribing, Recording, and Reporting Brachytherapy For Cancer of the Cervix. Prepared in collaboration with Groupe Europe ́en de Curiethe ́rapie – European Society for Radiotherapy and Oncology (GEC-ESTRO) (Published June 2016). // Journal of the ICRU. – 2013. – V. 13, N 1–2, 274 P.
  49. Vishwanathan A.N., Beriwal S., De Los Santos J.F. et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose- rate brachytherapy. // Brachytherapy. – 2012. – V. 11. – P. 47–52.
  50. Hellebust T.A., Kirisits C., Berger D. Recommendations for gynaecological (GYN) GEC-ESTRO working group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. // Radiotherapy and Oncology. – 2010. – V. 96. – P. 153–160.
  51. Monk BJ., Wang J., Im S. et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. // Gynecol Oncol. – 2005. – V. 96. – P. 721–728.
  52. Chernofsky MR, Felix JC, Muderspach LI, et al. Influence of quantity of lymph vascular space invasion on time to recurrence in women with early-stage squamous cancer of the cervix. GynecolOncol 2006;100:288-293.
  53. Marchiole P, Buenerd A, Benchaib M, et al. Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case-control surgico- pathological study. GynecolOncol 2005;97:727-732.
  54. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J ClinOncol 2008;26:5802- 5812
  55. Pearcey R, Miao Q, Kong W, et al. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. J ClinOncol 2007;25:2383-2388.
  56. Mileshkin LR, Narayan K, Moore KN, et al. A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174) [abstract]. Journal of Clinical Oncology 2014 32:abstract TPS5632.
  57. Gong L, Lou JY, Wang P, et al. Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer. Int J GynaecolObstet 2012;117:23-26.
  58. Eddy GL, Bundy BN, Creasman WT, et al. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. GynecolOncol 2007;106:362-369.
  59. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2010:CD007406
  60. Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer 2013;108:1957-1963
  61. Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J SurgOncol 2013;39:115-124
  62. Kim JS, Kim SY, Kim KH, Cho MJ. Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J RadiatOncolBiolPhys 2003;55:1247- 1253.
  63. Chung YL, Jian JJ, Cheng SH, et al. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study. GynecolOncol 2005;97:126-135
  64. Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015;16:301-311
  65. Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J ClinOncol 2015;33:2129-2135
  66. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. GynecolOncol 2007;105:299-303
  67. Lorusso D, Petrelli F, Coinu A, et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. GynecolOncol 2014;133:117-123
  68. Leath CA, 3rd, Straughn JM, Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. GynecolOncol 2013;129:251-257
  69. Wagenaar HC, Pecorelli S, Mangioni C, et al. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. Eur J Cancer 2001;37:1624-1628.
  70. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J ClinOncol 1997;15:625-631
  71. Garcia AA, Blessing JA, Vaccarello L, Roman LD. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J ClinOncol 2007;30:428-431
  72. Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. GynecolOncol 2005;96:103-107.

Для продолжения работы требуется вход / регистрация